Maggio-Cavaliere M E
Pharmacology. 1976;14(3):274-87. doi: 10.1159/000136605.
Acetylsecohemicholinium No. 3 (AcHC-3), the acetate of the open ring (seco form of hemicholinium No. 3, HC-3) hydrolyzes in vitro to the hemiacetal HC-3 at pH values above 9, a temperature-dependent conversion illustrated by ultraviolet spectral shifts from 305 to 257 mmu, and to a limited extent by certain esterases as measured by manometric analysis. An LD50 of 125 mug/kg for a neutral solution of AcHC-3 was decreased to 78.3 mug/kg (the LD50 of HC-3) upon being made basic. Prolonged treatment of mice with LD10-20 doses of AcHC-3 was associated with decreased fatty acid oxidation in the liver and resulted in infiltration of fat into hepatic cells, a reaction preventable by treatment with small doses of choline (10 mg/kg). AcHC-3 causes neuromuscular and autonomic ganglionic blockade, cholinesterase inhibition, and in vitro inhibition of acetylcholine (ACh) synthesis. These actions, although HC-3-like, appear to be due to AcHC-3 rather than HC-3 since neither cholinesterase inhibition nor hepatic ligation altered the neuromuscular blocking actions of AcHC-3. In addition to its HC-3-like properties, AcHC-3 consistently produced a transient increase in twitch height of gastrocnemius muscle before blockade and was dose-responsive in depressing blood pressure and in eliciting contractions of the isolated guinea pig ileum. AcHC-3 is both a cholinomimetic (depresses arterial blood pressure, decreases heart rate and increases ileal contractions) and a competitor of acetylcholine. That is, in most preparations tested, AcHC-3 at lower concentrations has as much intrinsic activity as ACh and at somewhat higher concentrations competitively blocks the responses to ACh. These cholinomimetic actions may be due to the presence of two ACh moieties on the AcHC-3 molecule which attach to cholinergic receptor sites. Also noted was an action of AcHC-3 that seems to be peculiar to the secohemicholiniums, namely, the potentiation of catechloamines.
乙酰半胱氨酸3号(AcHC-3),即开环(半胱氨酸3号的开环形式,HC-3)的醋酸盐,在体外pH值高于9时会水解为半缩醛HC-3,这种温度依赖性的转化通过紫外光谱从305纳米迁移到257纳米来体现,并且通过测压分析可知某些酯酶也能在一定程度上促使其转化。AcHC-3中性溶液的半数致死量为125微克/千克,碱化后降至78.3微克/千克(HC-3的半数致死量)。用LD10-20剂量的AcHC-3对小鼠进行长期治疗,会导致肝脏中脂肪酸氧化减少,并致使脂肪浸润到肝细胞中,而小剂量胆碱(10毫克/千克)治疗可预防这种反应。AcHC-3会引起神经肌肉和自主神经节阻断、胆碱酯酶抑制以及体外对乙酰胆碱(ACh)合成的抑制。这些作用虽然与HC-3类似,但似乎是由AcHC-3而非HC-3引起的,因为胆碱酯酶抑制和肝结扎均未改变AcHC-3的神经肌肉阻断作用。除了具有类似HC-3的特性外,AcHC-3在阻断前始终会使腓肠肌抽搐高度短暂增加,并且在降低血压和引发离体豚鼠回肠收缩方面呈剂量依赖性。AcHC-3既是拟胆碱剂(降低动脉血压、降低心率并增加回肠收缩)又是乙酰胆碱的竞争者。也就是说,在大多数测试制剂中,较低浓度的AcHC-3具有与ACh一样多的内在活性,而在稍高浓度时会竞争性阻断对ACh的反应。这些拟胆碱作用可能是由于AcHC-3分子上存在两个与胆碱能受体位点结合的ACh部分。还注意到AcHC-3有一种似乎是半胱氨酸独有的作用,即儿茶酚胺的增强作用。